Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 6/20 | 0.46 |
| ▸ | CA2 | P00918 | 6/20 | 0.46 |
| ▸ | CA12 | O43570 | 4/20 | 0.46 |
| ▸ | CA9 | Q16790 | 4/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4001822 | 0.88 | TDP1 (0.56) | TDP1GAAMEN1KMT2AMAOA | |
| SCHEMBL3341020 | 0.84 | TDP1 (0.67) | TDP1GAAMEN1KMT2AMAOA | |
| SCHEMBL22693649 | 0.84 | TDP1 (0.53) | TDP1GAAMEN1KMT2AMAOA | |
| SCHEMBL27769661 | 0.83 | TDP1 (0.56) | TDP1GAAMEN1KMT2AMAOA | |
| SCHEMBL2799440 | 0.83 | TDP1 (0.56) | TDP1GAAMEN1KMT2AMAOA | |
| SCHEMBL156911 | 0.83 | GAA (0.58) | TDP1GAAMEN1KMT2AMAOA | |
| SCHEMBL17790280 | 0.82 | TDP1 (0.51) | TDP1GAAMEN1KMT2AMAOA | |
| SCHEMBL7765884 | 0.82 | TDP1 (0.55) | TDP1GAAMEN1KMT2AMAOA | |
| SCHEMBL7434241 | 0.82 | TDP1 (0.59) | TDP1GAAMEN1KMT2AMAOA | |
| SCHEMBL7757680 | 0.82 | TDP1 (0.55) | TDP1GAAMEN1KMT2AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2502911-B1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMA (US) | 2017-04-05 | — | — | EP | claimed |
| US-20150336898-A1 | Prodrugs of Modulators of ABC Transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2015-11-26 | — | — | US | claimed |
| US-20150315186-A2 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2015-11-05 | — | — | US | claimed |
| US-20150231142-A1 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMA (US) | 2015-08-20 | — | — | US | claimed |
| US-20150150879-A2 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMACEUTICALS INCORPORATED | 2015-06-04 | — | — | US | claimed |
| US-20150065487-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMA (US) | 2015-03-05 | — | — | US | claimed |
| US-20150031722-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2015-01-29 | — | — | US | claimed |
| US-20140329814-A2 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMA (US) | 2014-11-06 | — | — | US | claimed |
| US-20140243289-A1 | PRODRUGS OF MODULATORS OF ABC TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-28 | — | — | US | claimed |
| US-20140187770-A9 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-07-03 | — | — | US | claimed |
| EP-1865949-B1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMA (US) | 2012-11-14 | — | — | EP | claimed |
| EP-2502911-A2 | Modulators of ATP-binding cassette transporters | Vertex Pharmaceuticals Incorporated (US) | 2012-09-26 | — | — | EP | claimed |
| CN-102665715-A | Compositions for treatment of cystic fibrosis and other chronic diseases | VERTEX PHARMA | 2012-09-12 | — | — | CN | claimed |
| US-20110098311-A1 | COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES | Vertex Pharmaceuticals Incorported (US) | 2011-04-28 | — | — | US | claimed |
| CN-101935301-A | Modulators of ATP-binding cassette transporters | VERTEX PHARMA | 2011-01-05 | — | — | CN | claimed |
| CN-101891680-A | The adjusting control agent of ATP- combination cassette transporters | VERTEX PHARMA | 2010-11-24 | — | — | CN | claimed |
| US-20090105272-A1 | Prodrugs of modulators of ABC transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2009-04-23 | — | — | US | claimed |
| CN-101374849-A | Quinolin-4-one derivatives as ABC transporter modulators | VERTEX PHARMA (US) | 2009-02-25 | — | — | CN | claimed |
| CN-101006076-A | Modulators of ATP-binding cassette transporters | VERTEX PHARMA (US) | 2007-07-25 | — | — | CN | claimed |
| US-20060074075-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), used for treating genetic disorders; respiratory system disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2006-04-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031722-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | TDP1 4130/4885GAA 454/4885MEN1 4698/4885 |
| US-20110098311-A1 | COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES | CFTR, SLC26A4, ABCB11 | TDP1 4520/4885GAA 969/4885MEN1 3122/4885 |
| US-20140329814-A2 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | CFTR, SLC26A4, ABCB11 | TDP1 4520/4885GAA 969/4885MEN1 3122/4885 |
| US-20140187770-A9 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | TDP1 4130/4885GAA 454/4885MEN1 4698/4885 |
| US-20090105272-A1 | Prodrugs of modulators of ABC transporters | ABCB1, CFTR, ABCB11 | TDP1 1328/4885GAA 296/4885MEN1 4003/4885 |
| US-20150065487-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | TDP1 4130/4885GAA 454/4885MEN1 4698/4885 |
| US-20150315186-A2 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | TDP1 4130/4885GAA 454/4885MEN1 4698/4885 |
| US-20150231142-A1 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | CFTR, SLC26A4, ABCB11 | TDP1 4520/4885GAA 969/4885MEN1 3122/4885 |
| US-20150336898-A1 | Prodrugs of Modulators of ABC Transporters | ABCB1, CFTR, ABCB11 | TDP1 1328/4885GAA 296/4885MEN1 4003/4885 |
| US-20060074075-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), used for treating genetic disorders; respiratory system disorders | CFTR, ABCC4, ABCC2 | TDP1 4307/4885GAA 650/4885MEN1 4791/4885 |
| US-20140243289-A1 | PRODRUGS OF MODULATORS OF ABC TRANSPORTERS | ABCB1, CFTR, ABCB11 | TDP1 1328/4885GAA 296/4885MEN1 4003/4885 |
| US-20150150879-A2 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | CFTR, SLC26A4, ABCB11 | TDP1 4520/4885GAA 969/4885MEN1 3122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.